These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34199304)

  • 41. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
    Peng J; Sridhar S; Siefker-Radtke AO; Selvarajah S; Jiang DM
    Curr Treat Options Oncol; 2022 Sep; 23(9):1269-1287. PubMed ID: 35962938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
    Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
    Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma.
    Benjamin DJ; Mar N; Rezazadeh Kalebasty A
    Clin Med Insights Oncol; 2022; 16():11795549221126252. PubMed ID: 36186672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
    Loriot Y; O'Hagan A; Siefker-Radtke AO
    Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
    Roubal K; Myint ZW; Kolesar JM
    Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infigratinib: First Approval.
    Kang C
    Drugs; 2021 Jul; 81(11):1355-1360. PubMed ID: 34279850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use.
    Puar A; Donegan D; Helft P; Kuhar M; Webster J; Rao M; Econs M
    AACE Clin Case Rep; 2022; 8(5):217-220. PubMed ID: 36189136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
    Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
    Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
    de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
    JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma.
    Sayegh N; Tripathi N; Agarwal N; Swami U
    Onco Targets Ther; 2022; 15():1047-1055. PubMed ID: 36186154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erdafitinib for the treatment of urothelial cancer.
    Marandino L; Raggi D; Giannatempo P; Farè E; Necchi A
    Expert Rev Anticancer Ther; 2019 Oct; 19(10):835-846. PubMed ID: 31544541
    [No Abstract]   [Full Text] [Related]  

  • 55. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
    Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
    Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting.
    Salati M; Caputo F; Baldessari C; Carotenuto P; Messina M; Caramaschi S; Dominici M; Bonetti LR
    Cancer Manag Res; 2021; 13():7747-7757. PubMed ID: 34675670
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated
    d'Arienzo PD; MacDonald AR; Patel V; Ma YT; Pihlak R; Starling N
    Onco Targets Ther; 2024; 17():489-496. PubMed ID: 38895132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
    Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
    Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
    Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinicogenomic Analysis of
    Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
    Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.